Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg News

Novartis, Pfizer Said to Be Out of Bidding in Onyx Auction (2)

August 13, 2013

Novartis Is Said to Be Out of Bidding for Onyx Pharmaceuticals

The Novartis AG logo is seen on the company's headquarters in Basel, Switzerland. Photographer: Adrian Moser/Bloomberg

Novartis AG (NOVN) and Pfizer (PFE:US) Inc. won’t bid for Onyx Pharmaceuticals Inc. (ONXX:US), the maker of cancer drugs, leaving Amgen Inc. with only one possible rival bidder remaining, according to people familiar with the situation.

Onyx’s current valuation makes it too expensive for Novartis, said one of the people, who asked not to be identified because the matter is private. Pfizer recently backed away from making a bid and is no longer doing due diligence, said one of the people. London-based AstraZeneca Plc is still doing due diligence, that person said.

Novartis, AstraZeneca and New York-based Pfizer had expressed interest in South San Francisco, California-based Onyx, the maker of Kyprolis, a blood cancer drug approved last year for some patients. Amgen upped its initial $120-a-share bid to $130 a share last week, a person familiar with the matter said then. If AstraZeneca doesn’t bid, Amgen, the world’s biggest biotechnology company by sales, would have no competition.

Novartis, based in Basel, Switzerland, still has people doing due diligence at Onyx, one of the people said. None of the other companies, including AstraZeneca, has made a bid to rival Thousand Oaks, California-based Amgen’s $130-a-share offer, the person said.

Onyx is involved with several potential purchasers, Chief Executive Officer N. Anthony Coles said Aug. 9.

Lori Melancon, a spokeswoman for Onyx, said the company wouldn’t comment on rumors and speculation. Novartis spokesman Eric Althoff, Pfizer spokeswoman Joan Campion and AstraZeneca spokeswoman Esra Erkal-Paler declined to comment.

Onyx declined less than 1 percent to $124.88 at the close in New York, giving the company a market value of about $9.16 billion.

To contact the reporters on this story: Kristen Hallam in London at; David Welch in New York at

To contact the editors responsible for this story: Phil Serafino at; Reg Gale at

blog comments powered by Disqus